Antisense and RNAi Therapeutics Market Poised for Robust 17.8% CAGR Growth to $18.43 Billion by 2032 Driven by Orphan Diseases, Delivery Advancements, and North American Leadership
-
Global antisense and RNAi therapeutics market size valued at USD 4.34 billion in 2023, projected to reach USD 18.43 billion by 2032 with a 17.8% CAGR.
-
Key drivers include increasing focus on orphan and rare diseases, advancements in drug delivery methods, and rise in R&D investments.
-
North America accounted for the largest revenue share in 2023 due to leading pharma companies and research institutions.
-
Antisense RNA segment dominated with largest market share while intrathecal injections witnessed highest growth.
-
Key players include Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, and Sanofi.